US20030070584A1 - Dip coating compositions containing cellulose ethers - Google Patents

Dip coating compositions containing cellulose ethers Download PDF

Info

Publication number
US20030070584A1
US20030070584A1 US10/122,999 US12299902A US2003070584A1 US 20030070584 A1 US20030070584 A1 US 20030070584A1 US 12299902 A US12299902 A US 12299902A US 2003070584 A1 US2003070584 A1 US 2003070584A1
Authority
US
United States
Prior art keywords
percent
composition
coating
subcoating
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/122,999
Other languages
English (en)
Inventor
Cynthia Gulian
Walter Gowan
Kishor Parekh
Joseph Morris
Thomas Markley
Dennis Wieand
Gerard McNally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to US10/122,999 priority Critical patent/US20030070584A1/en
Priority to US10/122,498 priority patent/US20030072729A1/en
Priority to AU40617/02A priority patent/AU4061702A/en
Priority to AU40618/02A priority patent/AU4061802A/en
Priority to KR1020020026391A priority patent/KR20020087367A/ko
Priority to ARP020101763A priority patent/AR035899A1/es
Priority to CA002386430A priority patent/CA2386430A1/en
Priority to ES02253342T priority patent/ES2323526T3/es
Priority to EP02253342A priority patent/EP1260219B1/en
Priority to NZ518951A priority patent/NZ518951A/en
Priority to JP2002139176A priority patent/JP2003089659A/ja
Priority to EP02253340A priority patent/EP1260217A3/en
Priority to NZ518950A priority patent/NZ518950A/en
Priority to EP02253341A priority patent/EP1260218B1/en
Priority to AT02253342T priority patent/ATE427741T1/de
Priority to CA2386278A priority patent/CA2386278C/en
Priority to JP2002139169A priority patent/JP2003012561A/ja
Priority to ARP020101759A priority patent/AR034335A1/es
Priority to JP2002139178A priority patent/JP2003012560A/ja
Priority to ARP020101762A priority patent/AR036998A1/es
Priority to KR1020020026456A priority patent/KR20020087370A/ko
Priority to DE60231850T priority patent/DE60231850D1/de
Priority to MXPA02004824A priority patent/MXPA02004824A/es
Priority to AT02253341T priority patent/ATE516798T1/de
Priority to MXPA02004823A priority patent/MXPA02004823A/es
Priority to CA2386339A priority patent/CA2386339C/en
Priority to BR0201904-3A priority patent/BR0201904A/pt
Priority to CO02041349A priority patent/CO5400143A1/es
Priority to BR0202523A priority patent/BR0202523A/pt
Priority to CN02121867A priority patent/CN1429545A/zh
Priority to CO02041350A priority patent/CO5390071A1/es
Priority to CN02121869A priority patent/CN1388189A/zh
Priority to KR1020020026834A priority patent/KR20020087380A/ko
Priority to CN02121868A priority patent/CN1388190A/zh
Priority to BR0201905-1A priority patent/BR0201905A/pt
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOWAN, WALTER G., JR., WIEAND, DENNIS C., GULIAN, CYNTHIA, MARKLEY, THOMAS J., MCNALLY, GERARD P., MORRIS, JOSEPH M, PAREKH, KISHOR B.
Publication of US20030070584A1 publication Critical patent/US20030070584A1/en
Priority to US11/769,028 priority patent/US7785650B2/en
Priority to US12/335,069 priority patent/US20090092739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Definitions

  • This invention relates to novel, water soluble, gelatin-free compositions for dip coating substrates, such as tablets and capsules, and methods for producing such dosage forms.
  • This invention further relates to a method for increasing the weight gain of a water soluble, gelatin-free, film forming coating on a dip-coated tablet or caplet.
  • empty hard gelatin capsules are manufactured using automated equipment.
  • This equipment employs rows of stainless steel pins, mounted on bars or plates, which are dipped into a gelatin solution maintained at a uniform temperature and fluidity. The pins are then withdrawn from the gelatin solution, rotated, and then inserted into drying kilns through which a strong blast of filtered air with controlled humidity is forced. A crude capsule half is thus formed over each pin during drying. Each capsule half is then stripped, trimmed to uniform length, filled and joined to an appropriate mating half.
  • caplets which are solid, oblong tablets that are often coated with various polymers such as cellulose ethers to improve their aesthetics, stability, and swallowability.
  • polymers such as cellulose ethers
  • spray-coated tablets lack the shiny surface and elegance of the hard gelatin capsules. Additionally, it is not commercially feasible to spray-coat a tablet with a different color coating on each end.
  • gelcaps are elegant, shiny, consumer-preferred dosage forms that are prepared by dipping each half of an elongated tablet in two different colors of gelatin solution. See U.S. Pat. Nos.: 4,820,524; 5,538,125; 5,685,589; 5,770,225; 5,198,227; and 5,296,233, which are all incorporated by reference herein.
  • a similar dosage form, commercially available as a “geltab,” is prepared by dipping each half of a round, convex tablet into different colors of gelatin solution, as described in U.S. Pat. Nos. 5,228,916, US5,436,026 and US5,679,406, which are all incorporated by reference herein.
  • such “gelcaps” and “geltabs” shall be included within the broader term, “tablets.”
  • gelatin as a pharmaceutical coating material presents certain disadvantages and limitations, including the potential for decreased dissolution rate after extended storage due to cross-linking of the gelatin, potential for microbial contamination of the gelatin solution during processing, and long processing times due to extensive drying requirements. Further, the energy-related costs associated with gelatin coatings tend to be high since the gelatin material is typically applied to the substrates at an elevated temperature of at least about 40° C. in order to maintain fluidity of the gelatin, while the substrates are maintained at about 50° C. in order to minimize microbial growth.
  • WO 00/18835 discloses the combination of starch ethers or oxidized starch and hydrocolloids for use in preparing hard capsule shells via conventional dip molding processing. See also U.S. Pat. No. 4,001211 (capsules prepared via pin dip coating with thermogelled methylcellulose ether compositions).
  • hard gelatin capsules are no longer a preferred delivery system for consumer (over-the-counter) pharmaceuticals, dietary supplements, or other such products.
  • compositions into which steel pins are to be dipped then dried to form hard capsule shells thereon are not necessarily the same as those for dipping tablets to form a coating thereon.
  • relevant physical properties such as viscosity, weight-gain, film thickness, tensile strength, elasticity, and moisture content will differ between compositions for hard capsule formation and for coating tablets. See e.g., U.S. Pat. No. 1,787,777 (Optimal temperatures of the substrate and coating solution, residence times in the solution, and drying conditions differ.)
  • One disadvantage associated with dipping tablets or capsules into a non-gelatin coating system is that the resulting coatings often lack adequate tensile strength, plasticity, hardness, and thickness.
  • non-gelatin coating systems often results in tablets having soft, tacky coatings without a hardness sufficient to maintain their shape or smoothness during handling.
  • many non-gelatin compositions do not adhere to the tablet substrate in an amount sufficient to uniformly cover the tablet after a single dipping.
  • many non-gelatin compositions lack the sufficient rheological properties necessary to maintain uniform color dispersion throughout the dipping and drying process.
  • the present invention provides for a film forming composition for dip coating a substrate comprising, consisting of, and/or consisting essentially of:
  • a thickener selected from the group consisting of xanthan gum, carrageenan, and mixtures thereof,
  • composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  • Another embodiment of the present invention is directed to a water soluble composition for dip-coating a substrate comprising, consisting of, and/or consisting essentially of:
  • composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  • Another embodiment of the present invention is directed to a water soluble composition for dip-coating a substrate comprising, consisting of, and/or consisting essentially of:
  • composition possesses a surface gloss of at least 150 when applied via dip coating to a substrate.
  • capsules refer to hard shell compartments that enclose a dosable ingredient.
  • Tablets refer to compressed or molded solid dosage forms of any shape or size.
  • Caplets refer to solid, oblong-shaped tablets.
  • Geltabs refer to solid tablets having flat sides, convex opposing faces, and a glossy gelatinous coating.
  • Hardness as used herein in connection with films or coatings indicates the resistance of the film/coating to deformation upon impact.
  • Water soluble as used herein in connection with non-polymeric materials, shall mean from sparingly soluble to very soluble, i.e., not more than 100 parts water required to dissolve 1 part of the non-polymeric, water soluble solute. See Remington, “The Science and Practice of Pharmacy,” pages 208-209 (2000). “Water soluble,” as used herein in connection with polymeric materials, shall mean that the polymer swells in water and can be dispersed at the molecular level to form a homogeneous dispersion or colloidal “solution.” “Surface gloss” as used herein, shall refer to amount of light reflectance as measured at a 60 degree incident angle using the method set forth in Example 7 herein.
  • Dimethicone is a well known pharmaceutical material consisting of linear siloxane polymers containing repeating units of the formula ⁇ —(CH 2 ) 2 SiO ⁇ n stabilized with trimethylsiloxy end blocking units of the formula [(CH 3 ) 3 SiO-].
  • Simethicone is the mixture of dimethicone and silicon dioxide.
  • the two materials may be used interchangably.
  • the first embodiment of this invention is directed to water soluble, substantially gelatin-free, film forming compositions for dip coating tablets or manufacturing capsules via a dip molding process.
  • One composition comprises, consists of, and/or consists essentially of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and a thickener, such as a hydrocolloid, e.g., xanthan gum or carrageenan.
  • the composition comprises, consists of, and/or consists essentially of a film former such as a modified starch selected from waxy maize starch, tapioca dextrin, and derivatives and mixtures thereof; a thickener selected from sucrose, dextrose, fructose, maltodextrin, polydextrose, and derivatives and mixtures thereof; and a plasticizer, e.g., polyethylene glycol, propylene glycol, vegetable oils such as castor oil, glycerin, and mixtures thereof.
  • a film former such as a modified starch selected from waxy maize starch, tapioca dextrin, and derivatives and mixtures thereof
  • a thickener selected from sucrose, dextrose, fructose, maltodextrin, polydextrose, and derivatives and mixtures thereof
  • a plasticizer e.g., polyethylene glycol, propylene glycol, vegetable oils such as castor oil, glycerin, and mixtures
  • the composition comprises, consists of, and/or consists essentially of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and optionally a plasticizer, such as vegetable oils, e.g., castor oil; and may optionally be substantially free of thickeners such as hydrocolloids, e.g. xanthan gum.
  • the composition comprises, consists of, and/or consists essentially of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; an extender, such as polycarbohydrates, e.g.
  • a plasticizer such as glycols, e.g., polyethylene glycol
  • thickeners such as hydrocolloids, e.g. xanthan gum.
  • substantially gelatin-free shall mean less than about 1 percent, e.g. less than about 0.5 percent, of gelatin in the composition, and “substantially free of thickeners” shall mean less than about 1 percent, e.g. less than about 0.01 percent, of thickeners in the composition.
  • Any film former known in the art is suitable for use in film forming composition of the present invention.
  • suitable film formers include, but are not limited to, polyvinylalcohol (PVA), hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, methylcellulose, hydroxypropylcellulose (HPC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), hydroxyethylhydroxypropylmethyl cellulose (HEMPMC), pre-gelatinized starches, and polymers and derivatives and mixtures thereof.
  • PVA polyvinylalcohol
  • HPC hydroxypropylcellulose
  • HEMC hydroxyethylmethylcellulose
  • HPMC hydroxypropylmethylcellulose
  • HBMC hydroxybutylmethylcellulose
  • HEEC hydroxyethylethylcellulose
  • HPMC 2910 is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl and from about 7% to about 12% hydroxylpropyl groups.
  • HPMC 2910 is commercially available from the Dow Chemical Company under the tradename, “Methocel E.” “Methocel E5,” which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20° C.
  • degree of substitution shall mean the average number of substituent groups attached to a anhydroglucose ring
  • hydroxypropyl molar substitution shall mean the number of moles of hydroxypropyl per mole anhydroglucose.
  • modified starches include starches that have been modified by crosslinking, chemically modified for improved stability, or physically modified for improved solubility properties.
  • pre-gelatinized starches or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility. Suitable modified starches are commercially available from several suppliers such as, for example, A. E. Staley Manufacturing Company, and National Starch & Chemical Company.
  • One suitable modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames, “Purity Gum” and “FilmSet”, and derivatives, copolymers, and mixtures thereof.
  • waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100 percent to about 88 percent of amylopectin.
  • Suitable tapioca dextrins include those available from National Starch & Chemical Company under the tradename, “Crystal Gum” or “K-4484,” and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the tradename, “Purity Gum 40,” and copolymers and mixtures thereof.
  • any thickener known in the art is suitable for use in the film forming composition of the present invention.
  • thickeners include but are not limited to hydrocolloids such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, and derivatives and mixtures thereof.
  • Additional suitable thickeners include sucrose, dextrose, fructose, maltodextrin, polydextrose, and the like, and derivatives and combinations thereof.
  • Suitable xanthan gums include those available from C. P. Kelco Company under the tradename, “Keltrol 1000,” “Xantrol 180,” or “K9B310.”
  • plasticizer known in the pharmaceutical art is suitable for use in the present invention, and may include, but not be limited to polyethylene glycol; glycerin; sorbitol; triethyl citrate; tribuyl citrate; dibutyl sebecate; vegetable oils such as castor oil; surfactants such as polysorbates, sodium lauryl sulfates, and dioctyl-sodium sulfosuccinates; propylene glycol; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums and mixtures thereof.
  • an optional plasticizer may be present in an amount, based upon the total weight of the solution, from about 0 percent to about 40 percent.
  • the film forming composition for dip coating substrates may be substantially free of gelatin, i.e., e.g. contains less than about 1%, or less than about 0.01% of gelatin.
  • the film forming composition for dip coating substrates may be substantially free of bovine derived materials, i.e., e.g. contains less than about 1%, or less than about 0.01% of bovine derived materials.
  • the film forming composition for dip coating substrates may be substantially free of hydrocolloids, i.e., e.g. contains less than about 1%, or less than about 0.01% of hydrocolloids.
  • the film forming composition for dip coating substrates may be substantially free of plasticizers, i.e., e.g. contains less than about 1%, or less than about 0.01% of plasticizers.
  • the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to less than about 100 percent, e.g. from about 95 percent to about 99.5 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and from about 0.5 percent to about 5 percent of a thickener such as a hydrocolloid, e.g., xanthan gum.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose
  • a thickener such as a hydrocolloid, e.g., xanthan gum.
  • the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 40 percent to about 60 percent, e.g. from about 50 percent to about 55 percent, of a modified starch, e.g.
  • a waxy maize starch a tapioca dextrin, and/or mixtures and derivatives thereof; from about 15 percent to about 30 percent, e.g., from about 20 percent to about 25 percent of a plasticizer, e.g., glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof; and from about 5 percent to about 25 percent, e.g., from about 10 percent to about 20 percent, of a thickener, e.g., sucrose, dextrose, fructose, maltodextrin, polydextrose, and mixtures thereof.
  • a plasticizer e.g., glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof
  • a thickener e.g., sucrose, dextrose, fructose, maltodextrin, polydextrose, and mixtures thereof.
  • the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to about 100 percent, e.g. from about 97 percent to about 100 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose.
  • the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to about 100 percent, e.g. from about 97 percent to about 100 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose, and is substantially free of hydrocolloids, i.e., e.g. contains less than about 1%, or less than about 0.01% of hydrocolloids.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose
  • the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 95 percent to about 100 percent, e.g. from about 97 percent to about 100 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and from about 0.1 percent to about 1.0 percent, e.g. from about 0.25 percent to about 0.5 percent of a plasticizer such as vegetable oils, e.g. Castor Oil.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose
  • a plasticizer such as vegetable oils, e.g. Castor Oil.
  • the film forming composition for dip coating substrates contains, based upon the total dry solids weight of the composition, from about 5 percent to about 99 percent, e.g. from about 50 percent to about 90 percent, or from about 80 percent to about 90 percent of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; from about 1 percent to about 80 percent, e.g. from about 5 percent to about 50 percent or from about 5 percent to about 40 percent of an extender, such as polycarbohydrates, e.g. maltodextrin; and from about 0.1 percent to about 20 percent, e.g. from about 2.5 percent to about 15 percent of a plasticizer such as glycols, e.g. polyethylene glycol.
  • suitable dry compositions are disclosed in, for example, U.S. Pat. Nos. 5,470,581 and 6,183,808, which are incorporated by reference herein.
  • These film forming compositions are typically in the form of a dispersion for ease of dip coating substrates therein.
  • Such dispersions contain a solvent in an amount, based upon the total weight of the dispersion, from about 30 percent to about 97 percent, for example, from about 80 percent to about 92 percent or from about 40 percent to about 75 percent.
  • suitable solvents include, but are not limited to water; alcohols such as methanol, ethanol, and isopropanol; organic solvents such as methylene chloride, acetone, and the like; and mixtures thereof.
  • the solvent is water.
  • the resulting film forming dispersion typically possesses a solids level of, based upon the total weight of the film forming dispersion, from about 3 percent to about 70 percent, for example, from about 8 percent to about 20 percent or from about 25 percent to about 60 percent.
  • the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 20 percent, e.g. from about 8 percent to about 15 percent or from about 10 percent to about 14 percent, of a film former such as hydroxypropylmethylcellulose and from about 0.05 percent to about 0.2 percent, e.g. from about 0.08 percent to about 0.16 percent or from about 0.1 percent to about 0.14 percent, of a thickener such as xanthan gum.
  • a film former such as hydroxypropylmethylcellulose
  • a thickener such as xanthan gum
  • the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 20 percent to about 35 percent, e.g. from about 25 percent to about 30 percent, of a film former such as waxy maize starch, tapioca dextrin, and/or derivatives and mixtures thereof; from about 5 percent to about 20 percent, e.g., from about 10 percent to about 15 percent of a plasticizer such as glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof; and from about 5 percent to about 15 percent of a thickener selected from sucrose, fructose, dextrose, maltodextrin, polydextrose, and mixtures thereof.
  • a film former such as waxy maize starch, tapioca dextrin, and/or derivatives and mixtures thereof
  • a plasticizer such as glycerin, polyethylene glycol, propylene glycol, castor oil, and mixtures thereof
  • the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 25 percent, e.g. from about 8 percent to about 20 percent or from about 10 to about 16 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose.
  • the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 25 percent, e.g. from about 8 percent to about 20 percent or from about 10 to about 16 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose, and is substantially free of hydrocolloids, i.e., e.g. contains less than about 1%, or less than about 0.01% of hydrocolloids.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose
  • the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 5 percent to about 25 percent, e.g. from about 8 percent to about 20 percent or from about 10 to about 16 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; and from about 0.001 percent to about 0.1 percent, e.g. from about 0.01 percent to about 0.09 percent of a plasticizer such as vegetable oils, e.g. castor oil.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose
  • a plasticizer such as vegetable oils, e.g. castor oil.
  • the film forming composition for dip coating substrates contains, based upon the total wet weight of the dipping dispersion composition, from about 1 percent to about 21 percent, e.g. from about 10 percent to about 19 percent or from about 16 percent to about 19 percent, of a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose; from about 0.1 percent to about 17 percent, e.g. from about 1 percent to about 11 percent or from about 1 percent to about 8 percent of an extender, such as polycarbohydrates, e.g. maltodextrin; and from about 0.02 percent to about 4 percent, e.g. from about 0.5 percent to about 3 percent of a plasticizer such as glycols, e.g. polyethylene glycol.
  • a film former such as a cellulose ether, e.g., hydroxypropylmethylcellulose
  • an extender such as polycarbohydrates, e.g. maltodextrin
  • a plasticizer such as
  • the composition for dipping may further comprise other ingredients such as, based upon the total weight of the dipping solution, from about 0 percent to about 2 percent preservatives such as methylparaben and propylparaben, from about 0 percent to about 14 percent opacifying agents such as titanium dioxide, and/or from about 0 percent to about 14 percent colorants. See Remington's Practice of Pharmacy, Martin & Cook, 17th ed., pp. 1625-30, which is herein incorporated by reference.
  • Any coloring agent suitable for use in pharmaceutical applications may be used in the present invention and may include, but not be limited to azo dyes, quinopthalone dyes, triphenylmethane dyes, xanthene dyes, indigoid dyes, iron oxides, iron hydroxides, titanium dioxide, natural dyes, and mixtures thereof.
  • suitable colorants include, but are not limited to patent blue V, acid brilliant green BS, red 2G, azorubine, ponceau 4R, amaranth, D&C red 33, D+C red 22, D+C red 26, D+C red 28, D+C yellow 10, FD+C yellow 5, FD+C yellow 6, FD+C red 3, FD+C red 40, FD+C blue 1, FD+C blue 2, FD+C green 3, brilliant black BN, carbon black, iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, riboflavin, carotenes, antyhocyanines, turmeric, cochineal extract, clorophyllin, canthaxanthin, caramel, betan in, and mixtures thereof.
  • each end of the tablet or capsule may be coated with dip coatings of different colors to provide a distinctive appearance for specialty products. See U.S. Pat. No. 4,820,524, which is incorporated by reference herein.
  • the pharmaceutical dosage form is comprised of a) a core containing an active ingredient; b) an optional first coating layer comprised of a subcoating that substantially covers the core; and c) a second coating layer on the surface of the first coating layer, the second coating layer comprised of the dip coating composition of the present invention.
  • substantially covers shall mean at least about 95 percent of the surface area of the core is covered by the subcoating.
  • a first active ingredient may be contained in the first coating layer, and the core may contain a second active ingredient and/or an additional amount of the first active ingredient.
  • the active ingredient may be contained in the first coating layer, and the core may be substantially free, i.e., less than about 1 percent, e.g. less than about 0.1 percent, of active ingredient.
  • subcoatings are well known in the art and disclosed in, for example, U.S. Pat. Nos. 3,185,626, which is incorporated by reference herein. Any composition suitable for film-coating a tablet may be used as a subcoating according to the present invention. Examples of suitable subcoatings are disclosed in U.S. Pat. Nos. 4,683,256, 4,543,370, 4,643,894, 4,828,841, 4,725,441, 4,802,924, 5,630,871, and 6,274,162, which are all incorporated by reference herein.
  • cellulose ethers such as hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxyethylcellulose
  • polycarbohydrates such as xanthan gum, starch, and maltodextrin
  • plasticizers including for example, glycerin, polyethylene glycol, propylene glycol, dibutyl sebecate, triethyl citrate, vegetable oils such as castor oil, surfactants such as polysorbate-80, sodium lauryl sulfate and dioctyl-sodium sulfosuccinate
  • polycarbohydrates pigments, and opacifiers.
  • the subcoating may be comprised of, based upon the total weight of the subcoating, from about 2 percent to about 8 percent, e.g. from about 4 percent to about 6 percent of a water-soluble cellulose ether and from about 0.1 percent to about 1 percent, castor oil, as disclosed in detail in U.S. Pat. No. 5,658, 589, which is incorporated by reference herein.
  • the subcoating may be comprised of, based upon the total weight of the subcoating, from about 20 percent to about 50 percent, e.g., from about 25 percent to about 40 percent of HPMC; from about 45 percent to about 75 percent, e.g., from about 50 percent to about 70 percent of maltodextrin; and from about 1 percent to about 10 percent, e.g., from about 5 percent to about 10 percent of PEG 400.
  • the dried subcoating typically is present in an amount, based upon the dry weight of the core, from about 0 percent to about 5 percent.
  • the dried dip coating layer typically is present in an amount, based upon the dry weight of the core and the optional subcoating, from about 1.5 percent to about 10 percent.
  • the average thickness of the dried dip coating layer typically is from about 40 to about 400 microns.
  • the dip coating thickness may be varied in order to provide a smoother, easier to swallow, dosage form or to achieve a desired dissolution profile.
  • the thickness of dipped film coatings may vary at different locations on the substrate depending upon its shape. For example, the thickness of the coating at an edge or corner of a substrate may be as much as 50 percent to 70 percent less than the thickness of the coating at the center of a major face of the substrate. This difference can be minimized by, for example, use of a thicker subcoating, or use of dipping compositions that result in higher weight gains on the substrate.
  • a weight gain enhancer selected from the group consisting of simethicone, polysorbate 80 and mixtures thereof, may be added to a film forming composition comprised, consisting of, and/or consisting essentially of a film former and an optional thickener such as a hydrocolloid.
  • the weight gain enhancer is used in an amount sufficient to increase the weight gain of the coating solution, e.g. by at least about 10 percent, by at least about 20%, or by at least about 30% on a substrate when dried.
  • the percent weight gain increase is determined based upon the difference between the total weight of the coated substrate with the coating composition including the weight gain enhancer, and the total weight of an coated equivalent substrate, which has been coated under similar processing conditions with a coating composition that does not include an effective amount of weight gain enhancer.
  • the film former is a cellulose ether such as HPMC
  • the thickener is a hydrocolloid such as xanthan gum and the weight gain enhancer is simethicone.
  • a suitable film forming composition capable of achieving increased weight gain of dip coating on a substrate may contain, based upon the total dry weight of the film forming composition, from about 40 percent to about 99.9 percent, e.g. from about 95 percent to about 99.5 percent, or from about 40 percent to about 60 percent of a film former; from about 0 percent to about 60 percent , e.g. from about 0 percent to about 10 percent, or from about 0.5 percent to about 5 percent, or from about 10 percent to about 25 percent of a thickener; and from about 0.01 percent to about 0.25 percent, e.g. from about 0.03 percent to about 0.15 percent of a weight gain enhancer.
  • the amount of thickener suitable for use in the composition will vary depending upon, for example, the particular thickener selected and the desired properties of the coating.
  • the amount of xanthan gum thickener may range, based upon the total dry weight of the film forming composition, from about 0.5 percent to about 5 percent.
  • the film forming compositions of the present invention may be prepared by combining the film former, the thickener, and any optional ingredients such as plasticizers, preservatives, colorants, opacifiers, the weight gain enhancer, or other ingredients with the solventusing a high shear mixer until homogeneous under ambient conditions.
  • the mixture may be heated to a temperature of about 60° C. to about 90° C. for faster dispersion of the ingredients.
  • the film former and thickener may be preblended as dry powders, followed by addition of the resulting powder blend to the water and optional weight gain enhancer with high speed mixing.
  • the pressure may then be decreased to about 5 inches Hg while reducing the mixing speed in order to avoid creating a vortex therein. Any other additional optional ingredients may then be added thereto at constant mixing.
  • substrates may be dipped into such solutions of the present invention using the same equipment and similar range of process conditions as used for the production of dip molded, gelatin-coated tablets.
  • both tablets and hard capsules may be coated using the aqueous dispersions of the present invention via known gelatin-dipping process parameters and equipment. Details of such equipment and processing conditions are known in the art and are disclosed at, for example, U.S. Pat. No. 4,820,524, which is incorporated by reference herein.
  • the coating solutions of the present invention are fluid at room temperature and are less susceptible to microbial growth than gelatin compositions, the dip coating process may occur under ambient temperature and pressure conditions.
  • the tablets dip coated with the composition of the present invention may contain one or more active agents.
  • active agent is used herein in a broad sense and may encompass any material that can be carried by or entrained in the system.
  • the active agent can be a pharmaceutical, nutraceutical, vitamin, dietary supplement, nutrient, herb, foodstuff, dyestuff, nutritional, mineral, supplement, or favoring agent or the like and combinations thereof.
  • the active agents useful herein can be selected from classes from those in the following therapeutic categories: ace-inhibitors; alkaloids; antacids; analgesics; anabolic agents; anti-anginal drugs; anti-allergy agents; anti-arrhythmia agents; antiasthmatics; antibiotics; anticholesterolemics; anticonvulsants; anticoagulants; antidepressants; antidiarrheal preparations; anti-emetics; antihistamines; antihypertensives; anti-infectives; anti-inflammatories; antilipid agents; antimanics; anti-migraine agents; antinauseants; antipsychotics; antistroke agents; antithyroid preparations; anabolic drugs; antiobesity agents; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulcer agents; anti-uricemic agents; anxiolytic agents;
  • Active agents that may be used in the invention include, but are not limited to: acetaminophen; acetic acid; acetylsalicylic acid, including its buffered forms; acrivastine; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chlorohydrate and hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; amsacrine; amsalog; anethole; ascorbic acid; aspartame; astemizole; atenolol; azatidine and its maleate; bacitracin; balsam peru; BCNU (carmustine); beclomethasone diproprionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; benzquinamide and its hydrochloride; bethanechol; biotin; bisacodyl; bis
  • Active agents may further include, but are not limited to food acids; insoluble metal and mineral hydroxides, carbonates, oxides, polycarbophils, and salts thereof; adsorbates of active drugs on a magnesium trisilicate base and on a magnesium aluminum silicate base, and mixtures thereof. Mixtures and pharmaceutically acceptable salts of these and other actives can be used.
  • the dosage forms coated with the dip coatings of the present invention provided for immediate release of the active ingredient, i.e. the dissolution of the dosage form conformed to USP specifications for immediate release tablets containing the particular active ingredient employed.
  • the dosage form i.e. the dissolution of the dosage form conformed to USP specifications for immediate release tablets containing the particular active ingredient employed.
  • USP specifications for immediate release tablets containing the particular active ingredient employed.
  • U.S. Pat. No. 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, U.S. Pat. No.
  • the coatings formed by dipping substrates into the compositions of the present invention possessed excellent properties comparable to those possessed by gelatin coatings, e.g. crack resistance, hardness, thickness, color uniformity, smoothness, and gloss.
  • the coatings of the present invention possessed a surface gloss of greater than about 150, e.g. greater than about 190 or greater than about 210 when measured according to the method set forth in example 7 herein.
  • tablets dip coated with the compositions of the present invention were superior to tablets dip coated with conventional gelatin-based coatings in several important ways.
  • tablets dip coated with the compositions of the present invention advantageously retained acceptable dissolution characteristics for the desired shelf-life and storage period at elevated temperature and humidity conditions.
  • thehe cellulose-ether based compositions according to the present invention were also advantageously more resistant to microbial growth, which thereby enabled a longer shelf-life or use-life of the dipping solution as well as a reduction in manufacturing cost.
  • the sugar-thickened dipping dispersions according to the present invention beneficially employed a lower water content relative to that of gelatin-containing dispersions, which thereby enabled a shorter drying cycle time.
  • the water content of the other dipping dispersions of the present invention may have been higher than that typically found in gelatin-based dipping solutions, the cellulose-ether based compositions of the present invention surprisingly required a shorter drying cycle time relative to that for gelatin-containing compositions.
  • the dried coatings comprised of the compositions of the present invention also surprisingly and advantageously contained fewer air bubbles relative to the amount present in dried, gelatin based dipping compositions.
  • substrates may optionally be dipped in the solutions of the present invention at room temperature, which is economically more beneficial.
  • the dip coated compositions of the present invention possessed a higher degree of glossiness relative to similar coatings applied via spray coating methods known in the art.
  • the dip coated compositions of the present invention also possessed a similar degree of glossiness relative to that possessed by gelatin-containing dip or enrobing coatings, which are currently viewed as the industry benchmark for high gloss coatings. See, e.g., U.S. Pat. No.6,274,162 (Typical gloss readings for standard, commercially available gel-dipped or gelatin enrobed tablets range from about 200 to 240 gloss units, gloss readings for standard, commercialy available sugar-coated medicaments range from 177 to 209 gloss units, and gloss readings for a new, high-gloss coating system range from about 148 to about 243 gloss units.).
  • aqueous dispersion containing the ingredients set forth in Table A was prepared by combining all of the ingredients in a beaker under ambient conditions.
  • TABLE A Aqueous Dispersion Subcoating Composition Ingredient Part* HPMC (2910, 5 mPs) from 20 Dow Chemical Company under the tradename, “Methocel E-5” Castor oil 1 Water 241.5 Total Coating Solution 262.5 % solids in coating solution 8%
  • Compressed tablets were prepared in accordance with the procedure set forth in Example 1 of U.S. Pat. No. 5,658,589 (“'589 patent”), which was incorporated by reference herein.
  • Example 1 The dispersion of Example 1 was then applied onto the compressed tablets via spraying in accordance with the procedure set forth in the examples of the '589 patent. As shown in Table D below, the dried subcoated tablets possessed an average 2% to 4% weight gain relative to the weight of the subcoating-free tablets.
  • Example 1A to I H The percentage weight gain of the dried subcoated tablets are set forth below in Table D: TABLE D % Weight Gain of Dried Subcoated Tablets Example Number % Weight Gain 1A 2 1B 2 1C 4 1D 2 1E 4 1F 2 1G 4 1H 4
  • Aqueous HPMC dipping solutions containing the ingredients set forth in Table E were prepared: TABLE E Composition of HPMC Dipping Solutions Ingredient Ex 3A* (g) Ex 3B (g) Ex 3C (g) Ex 3D (%) Ex 3E (%) Ex 3F (%) HPMC E5 32.5 0 32.5 10 11 14 Water 200 200 89.89 88.879 85.85 HPMC 0 20 0 0 0 (2910, 15 mPs) Xanthan 0 0 0 0.11 0.121 0.15 gum PEG 400 0 0 8 0 0 % (wt.) 14 9 17 10.11 11.121 14.15 solids in dipping solution
  • HPMC was dispersed into 200 ml of deionized water at a temperature of 70° C. After adding about 1 wt % FD&C blue dye thereto, the solution was mixed until homogeneous. The solution was then cooled to a temperature of about 22° C.
  • Example 3A The procedure of Example 3A was repeated, but with substitution of HPMC (2910, 15 mPs) for the HPMC E5.
  • HPMC was dispersed into 200 ml of deionized water at a temperature of 70° C. After adding the PEG 400 thereto, the solution was mixed until homogeneous. The solution was then cooled to a temperature of about 22° C.
  • HPMC and xanthan gum were added to purified water at a temperature of 80° C. until the powder was dispersed. After discontinuing the heat, the solution was divided into two parts. 4.35 wt. % of a yellow color dispersion available from Colorcon, Inc. under the tradename, “Opatint Yellow DD-2115” was added to the first part and mixed at a low speed until dispersed. 5.8% of a green color dispersion available from Colorcon, Inc. under the tradename, “Opatint Green DD-11000” was added to the second part and mixed at a low speed until dispersed. The two dispersed solutions were then stored under ambient conditions for about 12 hours.
  • Example 3D The procedure of Example 3D was repeated, but using the components of Example 3E.
  • Example 3D was repeated, but using the components of Example 3F.
  • the coatings were smooth, hard, and shiny, and had no bubbles or cracking. However, the coatings were non-uniform and thin, with land areas not well-covered. Upon exposure to ambient conditions for a six month period, no cracks were seen in the coatings.
  • the coating were shiny, with few bubbles and no cracking.
  • the coatings were more uniform and rough relative to those of Example 3A.
  • the coatings were also somewhat tacky and thin, with land areas not well-covered. Upon exposure to ambient conditions for a six month period, no cracks were seen in the coatings.
  • the coatings were shiny with few bubbles and no cracking. The coatings were more uniform and rough relative to those of Example 3A. The coatings were also somewhat tacky and thin, with land areas not well-covered. Upon exposure to ambient conditions for a six month period, no cracks were seen in the coatings.
  • Example 3D The procedure of Example 3D was repeated, but using the components of Example 3I, as set forth in Table M: TABLE M Composition of HPMC Dipping Solutions Ingredient Ex 3I* (g) Ex 3J (g) HPMC E5 14 12 Water 85.89 87.88 HPMC (2910, 0 0 15 mPs) Xanthan gum 0.11 0.12 PEG 400 0 0 % (wt.) solids in 14.11 12.12 dipping solution
  • Example 3J Preparation of Dipping Solution of Example 3J
  • Example 3D The procedure of Example 3D was repeated, but using the components of Example 3J, as set forth in Table M above.
  • Dipping solutions comprised of the components set forth in Table G were prepared by dispersing 75 g of the modified waxy maize starch into 200 ml of water under ambient conditions with mixing: TABLE G Pre-gelatinized starch-containing Dipping solutions Component/Other Example 4A* Example 4B Modified waxy maize starch 75 125 (Purity ® Gum 59) water 200 200 Total weight of solution 275 325 Wt % solids in dipping solution 27 39
  • Example 4A Each side of the subcoated tablets prepared in accordance with Example 2 using the subcoating produced in Example I H were hand-dipped into the dipping solution of Example 4A for a dwell time of about 1 second, pulled up, then dried under ambient conditions.
  • the coatings were very shiny, hard, smooth, even, and not tacky or cracked. However, the coatings were too thin, and land areas were not covered. No cracking after exposure to ambient conditions for a period of 6 months.
  • the coatings were smooth and shiny. Initially the land areas were covered; however, the coatings cracked after exposure to ambient conditions for a period of 6 months.
  • the coatings possessed excellent shine and cover, and were smooth with no cracks. No cracking after exposure to ambient conditions for a period of 2 months.
  • Example 4C The procedure set forth in Example 4C is repeated, but without the inclusion of simethicone. Prior to coating the substrate, the solution is exposed to a vacuum pressure of 5 inches Hg in order to remove substantially all of the visible bubbles from the solution. The resulting coating possesses excellent shine and cover, and is smooth with no cracks.
  • Dipping solutions A through E, above, were prepared in the following manner: Purified water was heated to about 35° C. HPMC and xanthan gum were added while mixing using a laboratory scale electric mixer (Janke and Kunkel, IKA Labortechnik, Staufen, Germany) with propeller blade at approximately 1000 rpm until the powders appeared uniformly dispersed. Heating was discontinued, and the resulting dispersion was allowed to stand overnight at room temperature. Simethicone and yellow color dispersion were then added with mixing at approximately 500 rpm.
  • Subcoated cores prepared according to the method of example 1A, were pre-weighed, then dipped in solutions A, B, C, D, and E, above for a dwell time of about 2 seconds, pulled up, then dried at ambient conditions (about 22° C.). The cores were dipped simultaneously in sets of 7. Three separate sets of seven cores were dipped in each solution A through E. The average weight gain was determined from the triplicate sets of dipped cores from each coating solution.
  • This instrument utilized a CCD camera detector, employed a flat diffuse light source, compared tablet samples to a reference standard, and determined average gloss values at a 60 degree incident angle. During its operation, the instrument generated a grey-scale image, wherein the occurrence of brighter pixels indicated the presence of more gloss at that given location.
  • the instrument also incorporated software that utilized a grouping method to quantify gloss, i.e., pixels with similar brightness were grouped together for averaging purposes.
  • the “percent full scale” or “percent ideal” setting (also referred to as the “percent sample group” setting), was specified by the user to designate the portion of the brightest pixels above the threshold that will be considered as one group and averaged within that group.
  • “Threshold”, as used herein, is defined as the maximum gloss value that will not be included in the average gloss value calculation. Thus, the background, or the non-glossy areas of a sample were excluded from the average gloss value calculations.
  • the average surface gloss value for the reference standard was determined to be 269, using the 50% ideal (50% full scale) setting.
  • This Example showed that the tablets coated with the compositions of the present invention possessed a high surface gloss value that either was comparable to or exceeded that possessed by commercially-available gelatin coated tablets. In contrast, typical sprayed films possessed a substantially lower surface gloss, e.g. 119 to 125 in this Example.
  • Example 8A The resulting film coating dispersion was then applied onto the compressed acetaminophen tablets of Example 8A via spraying in accordance with the procedure set forth above in Example 8A.
  • the resulting spray coated tablets possessed a 4% weight gain relative to the weight of the uncoated tablet cores.
  • a dipping solution comprised of the components set forth in Table M below was produced: TABLE M HPMC/Castor Oil Clear Dipping Solutions Example A&B C&D E&F HPMC 2910 9% 13% 13% 5 mPs Castor Oil 0.04% 0.05% 0.05% Purified Water 90.96% 86.95% 86.95%
  • Example 8C-a The colorant of Example 8C-a was then added to 96 kg of the resulting clear dipping solutions with mixing at a 1750 rpm speed in the amounts set forth in Table N below: TABLE N HPMC/Castor Oil Colored Dipping Solutions
  • Subcoated tablets which were prepared in accordance with the procedure set forth above in Example 8A, were dip-coated with the dip-coating solution prepared in accordance with Example 8C-a and 8C-b using a commercial grade gel-dipping machine and in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein, using the dipping solution temperatures reported in the table above.
  • This procedure was independently repeated on subcoated tablets, which were prepared in accordance with the procedure set forth above in Example 8B, for each of the colored dipping solutions 8C-c through 8C-f in Table N above.
  • Subcoated tablets which were prepared in accordance with the procedure and materials set forth above in Example 8B, were dip-coated with the dip-coating solution prepared in accordance with this Example using a commercial grade gel-dipping machine and in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein, using a dipping solution temperature of 30° C.
  • the viscosity of the dipping solutions was 607 cPs at 30° C. for the yellow solution, and 677 cPs at 30° C. for the red solution. An average weight gain of about 27 mg/gelcap was obtained.
  • Subcoated tablets which were prepared in accordance with the procedure and materials set forth above in Example 8B, were dip-coated with the dip-coating solution prepared in accordance with this Example using a commercial grade gel-dipping machine and in accordance with the procedure described in U.S. Pat. No. 4,820,524, which is incorporated by reference herein, using a dipping solution temperature of 40° C. An average weight gain of about 20 mg/gelcap was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
US10/122,999 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers Abandoned US20030070584A1 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
US10/122,999 US20030070584A1 (en) 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers
US10/122,498 US20030072729A1 (en) 2001-05-15 2002-04-15 Simethicone as weight gain enhancer
AU40617/02A AU4061702A (en) 2001-05-15 2002-05-13 Dip coating compositions containing starch or dextrin
AU40618/02A AU4061802A (en) 2001-05-15 2002-05-13 Dip coating compostions containing cellulose ethers
ARP020101762A AR036998A1 (es) 2001-05-15 2002-05-14 Composiciones formadoras de peliculas, formas de dosificacion farmaceuticas y medicamento en forma de imitacion de capsula que las comprenden, un metodo para mejorar la uniformidad del color de una capa de la composicion de revestimiento y un metodo para incrementar el aumento de peso de una capa de
DE60231850T DE60231850D1 (de) 2001-05-15 2002-05-14 Zusammensetzungen zur Tauchbeschichtung enthaltend Celluloseether
CA002386430A CA2386430A1 (en) 2001-05-15 2002-05-14 Simethicone as weight gain enhancer
ES02253342T ES2323526T3 (es) 2001-05-15 2002-05-14 Composiciones para el recubrimiento por inmersion que comprenden esteres celulosicos.
EP02253342A EP1260219B1 (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers
NZ518951A NZ518951A (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin with a surface gloss value of at least 150 and contains less than 1% gelatine
JP2002139176A JP2003089659A (ja) 2001-05-15 2002-05-14 デンプンまたはデキストリンを含有しているディップ・コーティング組成物
EP02253340A EP1260217A3 (en) 2001-05-15 2002-05-14 Simethicone as weight gain enhancer for coating compositions
NZ518950A NZ518950A (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers with a gloss value of at least 150 and the coating is devoid of gelatine
EP02253341A EP1260218B1 (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin
AT02253342T ATE427741T1 (de) 2001-05-15 2002-05-14 Zusammensetzungen zur tauchbeschichtung enthaltend celluloseether
CA2386278A CA2386278C (en) 2001-05-15 2002-05-14 Dip coating compositions containing starch or dextrin
JP2002139169A JP2003012561A (ja) 2001-05-15 2002-05-14 セルロース・エーテルを含有しているディップ・コーティング組成物
ARP020101759A AR034335A1 (es) 2001-05-15 2002-05-14 Composiciones de revestimiento por inmersion que contienen eteres celulosa
JP2002139178A JP2003012560A (ja) 2001-05-15 2002-05-14 増量向上剤としてシメチコーンを用いている皮膜形成性組成物
KR1020020026391A KR20020087367A (ko) 2001-05-15 2002-05-14 전분 또는 덱스트린을 함유하는 침지 피복용 조성물
KR1020020026456A KR20020087370A (ko) 2001-05-15 2002-05-14 셀룰로즈 에테르를 함유하는 침지 피복용 조성물
ARP020101763A AR035899A1 (es) 2001-05-15 2002-05-14 Composiciones formadoras de pelicula, formas de dosificacion farmaceutica, medicamentos del tipo capsula simulados y metodo para preparar tabletas revestidas
MXPA02004824A MXPA02004824A (es) 2001-05-15 2002-05-14 Composiciones de revestimiento por inmersion que contienen almidon o dextrina.
AT02253341T ATE516798T1 (de) 2001-05-15 2002-05-14 Tauchbeschichtungszusammensetzungen enthaltend stärke oder dextrin
MXPA02004823A MXPA02004823A (es) 2001-05-15 2002-05-14 Composiciones de recubrimiento por inmersion que contienen eteres de celulosa.
CA2386339A CA2386339C (en) 2001-05-15 2002-05-14 Dip coating compositions containing cellulose ethers
CO02041349A CO5400143A1 (es) 2001-05-15 2002-05-15 Composiciones de recubrimiento por inmersion que contienen eteres de celulosa
KR1020020026834A KR20020087380A (ko) 2001-05-15 2002-05-15 증체량 증진제로서의 시메티콘
BR0202523A BR0202523A (pt) 2001-09-28 2002-05-15 Simeticona como realçador de ganho de peso
CN02121867A CN1429545A (zh) 2001-05-15 2002-05-15 作为增重增强剂的二甲基硅油
CO02041350A CO5390071A1 (es) 2001-05-15 2002-05-15 Composiciones de recubrimiento por inmersion que contienen almidon o extrina
CN02121869A CN1388189A (zh) 2001-05-15 2002-05-15 含有纤维素醚的浸涂组合物
BR0201904-3A BR0201904A (pt) 2001-05-15 2002-05-15 Composições de revestimento por imersão contendo éteres de celulose
CN02121868A CN1388190A (zh) 2001-05-15 2002-05-15 含有淀粉或糊精的浸涂组合物
BR0201905-1A BR0201905A (pt) 2001-05-15 2002-05-15 Composições para revestimento por imersão contendo amido ou dextrina
US11/769,028 US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms
US12/335,069 US20090092739A1 (en) 2001-05-15 2008-12-15 Method of dip-coating dosage forms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29112701P 2001-05-15 2001-05-15
US32572601P 2001-09-28 2001-09-28
US10/122,999 US20030070584A1 (en) 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/122,498 Continuation-In-Part US20030072729A1 (en) 2001-05-15 2002-04-15 Simethicone as weight gain enhancer
US10/122,531 Continuation-In-Part US20030072731A1 (en) 2001-05-15 2002-04-15 Dip coating compositions containing starch or dextrin
US11/769,028 Continuation US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms

Publications (1)

Publication Number Publication Date
US20030070584A1 true US20030070584A1 (en) 2003-04-17

Family

ID=27382893

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/122,999 Abandoned US20030070584A1 (en) 2001-05-15 2002-04-12 Dip coating compositions containing cellulose ethers
US11/769,028 Expired - Lifetime US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/769,028 Expired - Lifetime US7785650B2 (en) 2001-05-15 2007-06-27 Method for dip coating dosage forms

Country Status (15)

Country Link
US (2) US20030070584A1 (zh)
EP (1) EP1260219B1 (zh)
JP (1) JP2003012561A (zh)
KR (1) KR20020087370A (zh)
CN (1) CN1388189A (zh)
AR (1) AR034335A1 (zh)
AT (1) ATE427741T1 (zh)
AU (1) AU4061802A (zh)
BR (1) BR0201904A (zh)
CA (1) CA2386339C (zh)
CO (1) CO5400143A1 (zh)
DE (1) DE60231850D1 (zh)
ES (1) ES2323526T3 (zh)
MX (1) MXPA02004823A (zh)
NZ (1) NZ518950A (zh)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20050152971A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20070104754A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20070104755A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20070213411A1 (en) * 2003-11-05 2007-09-13 The Australian National University Dispersions And Methods Of Preparing Them
CN100358510C (zh) * 2005-04-27 2008-01-02 中国科学院海洋研究所 一种红藻多糖植物膳食纤维药用硬胶囊的制备方法
US20090074866A1 (en) * 2007-09-17 2009-03-19 Jen-Chi Chen Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US20090208574A1 (en) * 2008-02-19 2009-08-20 Jen-Chi Chen Dip coated compositions containing a starch having a high amylose content
US20110135694A1 (en) * 2009-12-07 2011-06-09 Saumitra Bagchi Partial dip coating of dosage forms for modified release
US8420057B2 (en) 2011-09-01 2013-04-16 Qualicaps, Inc. Capsule having broad color spectrum
US8435545B2 (en) 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429742B1 (en) * 2001-09-28 2011-05-04 McNeil-PPC, Inc. Modified release dosage forms
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06011871A (es) * 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
NZ551676A (en) * 2004-06-07 2010-11-26 Wyeth Corp Sugar coatings and methods therefor
US20060093560A1 (en) * 2004-10-29 2006-05-04 Jen-Chi Chen Immediate release film coating
GB2446865A (en) * 2007-02-21 2008-08-27 Dean William Dredge Temporary coating for revealing surface imperfections
CN101808667B (zh) * 2007-09-28 2012-11-21 琳得科株式会社 口服药剂
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
AU2011237122B2 (en) * 2010-03-31 2014-06-12 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
CN103813807B (zh) 2011-09-30 2017-02-08 持田制药株式会社 易服用性固体制剂
JP5908295B2 (ja) * 2012-02-03 2016-04-26 カバヤ食品株式会社 メントールを含む新規清涼菓子およびその製造方法
JP2013169146A (ja) * 2012-02-17 2013-09-02 Kabaya Shokuhin Kk 新規清涼菓子およびその製造方法
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
CA3029985A1 (en) 2016-07-05 2018-01-11 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Oral dosage form containing a fast release exterior coating
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5560926A (en) * 1993-02-10 1996-10-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the production of an S-ibuprofen-containing tablet
US5681684A (en) * 1995-09-20 1997-10-28 National Starch And Chemical Investment Holding Corporation Photosensitive resin composition
US5698220A (en) * 1988-08-30 1997-12-16 Pfizer Inc. Asymmetric membranes in delivery devices
US6113945A (en) * 1996-02-26 2000-09-05 L. Perrigo Company Multi-colored medicament

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1787777A (en) * 1926-12-10 1931-01-06 Parke Davis & Co Capsule machine
US3185626A (en) * 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US3652294A (en) 1970-08-19 1972-03-28 Nat Starch Chem Corp Manufacture of starch-containing food products
US3751277A (en) 1971-03-24 1973-08-07 Dow Chemical Co Tablet coating process and composition
US3802896A (en) * 1972-05-15 1974-04-09 Nutrilite Products Color concentrated base dispersion used in tablet film coating
US4001211A (en) * 1974-12-02 1977-01-04 The Dow Chemical Company Pharmaceutical capsules from improved thermogelling methyl cellulose ethers
GB1543167A (en) 1976-01-08 1979-03-28 Tate & Lyle Ltd Sweeteners
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4267164A (en) * 1980-01-31 1981-05-12 Block Drug Company Inc. Effervescent stannous fluoride tablet
US4313765A (en) * 1980-09-24 1982-02-02 Merck & Co., Inc. Synergistic blends of cellulase-free xanthan gum and cellulosics
US4683256A (en) 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
ATE10582T1 (de) 1981-01-22 1984-12-15 Capsugel A.G. Verfahren zur herstellung pharmazeutischer, darmloeslicher kapseln.
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
US4505890A (en) * 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
US4576646A (en) * 1983-07-06 1986-03-18 Seppic Film-forming compositions for enveloping solid forms, particularly pharmaceutical or food products or seeds, and products obtained, coated with said compositions
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
JPS61100519A (ja) * 1984-10-23 1986-05-19 Shin Etsu Chem Co Ltd 医薬用硬質カプセル
US4652313A (en) * 1984-10-24 1987-03-24 Crompton And Knowles Corporation Aqueous lake pigment suspension
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4853249A (en) 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US5023108A (en) * 1986-01-13 1991-06-11 Research Corporation Aqueous dispersions of waxes and lipids for pharmaceutical coating
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4802924A (en) * 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
US4820529A (en) * 1986-06-26 1989-04-11 Asahi Denka Kogyo Kabushiki Kaisha Process for preparing pasty proteinous material or proteinous food from crustaceans
JPS6362535A (ja) 1986-09-03 1988-03-18 Matsutani Kagaku Kogyo Kk 乳化剤の製造方法
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4981698A (en) * 1986-12-23 1991-01-01 Warner-Lambert Co. Multiple encapsulated sweetener delivery system and method of preparation
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4913893A (en) * 1987-08-28 1990-04-03 Clairol Incorporated Aerosol hair setting composition containing an alginate
JPH07100665B2 (ja) 1987-12-23 1995-11-01 信越化学工業株式会社 被覆薬剤の製造方法
US5164195A (en) 1988-04-19 1992-11-17 Southwest Research Institute Method of oral delivery with an adherent controlled-release salt sensitive capsule
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US4880636A (en) 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US4965089A (en) 1989-04-10 1990-10-23 Sauter Manufacturing Corp. Method and apparatus for the gelatin coating of caplets
NZ233403A (en) 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5059416A (en) 1989-06-26 1991-10-22 Warner-Lambert Company Zinc compound delivery system with improved taste and texture
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5248516A (en) 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
US5077053A (en) 1990-02-12 1991-12-31 Warner-Lambert Company Zein as a moisture barrier for sugarless edible compositions and method for preparing same
FR2660317B1 (fr) * 1990-03-27 1994-01-14 Seppic Produit filmogene destine a l'enrobage des formes solides; son procede de fabrication et produits revetus de ce produit.
WO1991015548A1 (en) * 1990-04-04 1991-10-17 Berwind Pharmaceutical Services, Inc. Aqueous maltodextrin and cellulosic polymer film coatings
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5136031A (en) 1990-07-09 1992-08-04 Tate & Lyle Public Limited Company Chlorination of sugars
CA2042529C (en) 1990-08-10 2002-07-30 Chokyun Rha Polysaccharide article and uses therefor
US5228909A (en) 1990-10-22 1993-07-20 Aqualon Company Sodium formate fluidized polymer suspensions
US5503673A (en) 1990-11-05 1996-04-02 Mcneil-Ppc, Inc Apparatus for dip coating product
US5538125A (en) 1990-11-05 1996-07-23 Mcneil-Ppc, Inc. Indexing and feeding systems for apparatus for gelatin coating tablets
US5228916A (en) 1990-11-05 1993-07-20 Mcneil-Ppc, Inc. Apparatus for creating a gelatin coating
US5436026A (en) 1990-11-05 1995-07-25 Mcneil-Ppc, Inc. Discharge and transfer system for apparatus for gelatin coating tablets
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5591455A (en) * 1990-12-20 1997-01-07 Warner-Jenkinson Company, Inc. Wet powder film-forming compositions
AU654991B2 (en) * 1990-12-20 1994-12-01 Warner-Jenkinson Company, Inc. Wet powder film-forming compositions
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
JP3279325B2 (ja) 1991-06-14 2002-04-30 チノン株式会社 自動焦点調節装置
ATE183642T1 (de) * 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical Tablette mit verzögerter freisetzung
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
KR100274734B1 (ko) 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 리제드로네이트 지연-방출성 조성물
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
JP3703481B2 (ja) * 1992-01-17 2005-10-05 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド セルロース重合体およびラクトースに基づくフィルム被覆および被覆組成物
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
US5286502A (en) * 1992-04-21 1994-02-15 Wm. Wrigley Jr. Company Use of edible film to prolong chewing gum shelf life
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5270071A (en) 1992-06-18 1993-12-14 Mcneil-Ppc, Inc. Reduced calorie fruit spreads
SG42869A1 (en) 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5382435A (en) * 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
DK0621032T3 (da) 1993-04-23 2000-10-23 Novartis Ag Lægemiddelform med reguleret afgivelse
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5635208A (en) * 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
CA2129079C (en) 1993-08-03 2006-01-17 Tatsuo Nomura Orally administrable cholesterol lowering agent
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
JPH09501947A (ja) * 1993-08-30 1997-02-25 ワーナー−ランバート・コンパニー 改良された錠剤コーティング方法
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
TW466119B (en) 1994-02-28 2001-12-01 Janssen Pharmaceutica Nv Film coated tablet of paracetamol and domperidone
IL112779A (en) 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
DE670160T1 (de) 1994-03-01 1996-03-14 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB2288813A (en) 1994-04-28 1995-11-01 Procter & Gamble Granular Detergent Composition
FR2719999B1 (fr) 1994-05-17 1996-08-02 Georges Serge Grimberg Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3355593B2 (ja) * 1994-08-19 2002-12-09 信越化学工業株式会社 固形腸溶製剤の製造方法
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5498709A (en) 1994-10-17 1996-03-12 Mcneil-Ppc, Inc. Production of sucralose without intermediate isolation of crystalline sucralose-6-ester
US6083430A (en) 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JP2959423B2 (ja) * 1994-12-01 1999-10-06 シオノギクオリカプス株式会社 カプセル用皮膜組成物
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
DE69518006T2 (de) * 1994-12-16 2000-12-21 Warner Lambert Co Verfahren zur einkapselung von tabletten in eine kapsel und feststoff-dosierungsformen erhaltbar durch dieses verfahren
US6245350B1 (en) * 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
EP0717992A3 (en) 1994-12-21 1998-03-25 McNEIL-PPC, INC. Aqueous suspension formulations for pharmaceutical applications
EP0807433A4 (en) 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JP3507211B2 (ja) 1995-07-13 2004-03-15 三菱化学株式会社 糖衣液及び糖衣錠
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
JP3225340B2 (ja) 1995-07-27 2001-11-05 株式会社新川 リードフレームの吸着保持装置
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
US5712310A (en) * 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
US5830503A (en) 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
GB9615283D0 (en) 1996-07-20 1996-09-04 Cerestar Holding Bv A method for precoating of chewing gum and a composition for the application in the said method
CN1088584C (zh) * 1996-08-02 2002-08-07 久光制药株式会社 口服制剂用胶囊及口服胶囊制剂
EP0958813B1 (en) * 1996-09-13 2005-04-06 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
EP0930874A2 (en) * 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5776479A (en) 1996-12-20 1998-07-07 The United States Of America As Represented By The Secretary Of Agriculture Stable, germicidal film-forming teat-dip solutions
US6183808B1 (en) * 1997-01-06 2001-02-06 Bpsi Holdings, Inc. Film coatings and film coating compositions based on dextrin
DE69825592T2 (de) * 1997-01-06 2005-08-11 BPSI Holdings, Inc., Wilmington Filmbeschichtungen und filmbeschichtungszusammensetzungen auf der basis von dextrin
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
RU2193880C2 (ru) 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
CA2294148A1 (en) * 1997-06-20 1998-12-30 Hitomi Izumi Gelled composition
NZ503086A (en) * 1997-08-29 2002-03-01 Upjohn Co An orally administrable pharmaceutical composition comprising an inner core and two outer layers, which render it substantially free of unpleasant tastes
US6066336A (en) * 1997-09-29 2000-05-23 Bristol-Myers Squibb Company Cholesterol-lowering tablets
EP1032425A1 (en) 1997-10-31 2000-09-06 Monsanto Company Gellan gum tablet coating
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP3051199U (ja) 1998-02-06 1998-08-11 ダイヤ製薬株式会社 鼻パック
CA2318782A1 (en) 1998-03-11 1999-09-16 Xiongwei He Polyvinyl alcohol compositions
NZ506928A (en) 1998-04-02 2003-09-26 Genencor Int A coating comprising a modified starch, a modified cellulose and optionally a plasticiser
US6270804B1 (en) 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
US6635275B1 (en) * 1999-01-29 2003-10-21 Warner-Lambert Company Modified starch film compositions
FR2783832A1 (fr) 1998-09-30 2000-03-31 Warner Lambert Co Compositions de film d'amidon modifie
ES2226418T5 (es) 1998-09-30 2009-01-01 Warner-Lambert Company Llc Composiciones para recubrimiento de almidon modificado.
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
DE60028730T2 (de) 1999-01-21 2006-12-28 Athpharma Ltd. Multipartikuläre bisoprolol formulierung
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
WO2000048574A1 (en) 1999-02-22 2000-08-24 Berwind Pharmaceutical Services, Inc. Elegant film coating system
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6340473B1 (en) * 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
ES2240148T3 (es) 1999-07-22 2005-10-16 Warner-Lambert Company Llc Composiciones en pelicula de pululano.
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
AU1195001A (en) 1999-10-11 2001-04-23 Monsanto Company Tablets coated with locust bean gum, guar gum or carrageenan gum
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6579545B2 (en) * 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698220A (en) * 1988-08-30 1997-12-16 Pfizer Inc. Asymmetric membranes in delivery devices
US5560926A (en) * 1993-02-10 1996-10-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the production of an S-ibuprofen-containing tablet
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5681684A (en) * 1995-09-20 1997-10-28 National Starch And Chemical Investment Holding Corporation Photosensitive resin composition
US6113945A (en) * 1996-02-26 2000-09-05 L. Perrigo Company Multi-colored medicament

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20070213411A1 (en) * 2003-11-05 2007-09-13 The Australian National University Dispersions And Methods Of Preparing Them
US10632078B2 (en) 2004-01-13 2020-04-28 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US11298324B2 (en) 2004-01-13 2022-04-12 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US8815290B2 (en) 2004-01-13 2014-08-26 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20050152971A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20110086098A1 (en) * 2004-01-13 2011-04-14 Rinker Roger A Rapidly disintegrating gelatinous coated tablets
US10092521B2 (en) 2004-01-13 2018-10-09 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US9149438B2 (en) 2004-01-13 2015-10-06 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
EP2098224A1 (en) 2004-07-23 2009-09-09 Mcneil-PPC, Inc Rapidly disintegrating gelatinous coated tablets
WO2006022805A1 (en) 2004-07-23 2006-03-02 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100358510C (zh) * 2005-04-27 2008-01-02 中国科学院海洋研究所 一种红藻多糖植物膳食纤维药用硬胶囊的制备方法
US8007825B2 (en) 2005-09-30 2011-08-30 Mcneil-Ppc, Inc. Oral compositions containing a salivation inducing agent
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US7879355B2 (en) * 2005-11-08 2011-02-01 Plensat Llc Method and system for treatment of eating disorders
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US20070104755A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20070104754A1 (en) * 2005-11-08 2007-05-10 Sterling Bernhard B Method and system for treatment of eating disorders
US20090074866A1 (en) * 2007-09-17 2009-03-19 Jen-Chi Chen Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
US8722089B2 (en) 2008-02-19 2014-05-13 Mcneil-Ppc, Inc. Dip coated compositions containing a starch having a high amylose content
US20090208574A1 (en) * 2008-02-19 2009-08-20 Jen-Chi Chen Dip coated compositions containing a starch having a high amylose content
WO2011071877A2 (en) 2009-12-07 2011-06-16 Mcneil-Ppc, Inc. Partial dip coating of dosage forms for modified release
US20110135694A1 (en) * 2009-12-07 2011-06-09 Saumitra Bagchi Partial dip coating of dosage forms for modified release
US9259394B2 (en) 2009-12-07 2016-02-16 Johnson & Johnson Consumer Inc. Partial dip coating of dosage forms for modified release
US8420057B2 (en) 2011-09-01 2013-04-16 Qualicaps, Inc. Capsule having broad color spectrum
US8435545B2 (en) 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum

Also Published As

Publication number Publication date
JP2003012561A (ja) 2003-01-15
ATE427741T1 (de) 2009-04-15
EP1260219A2 (en) 2002-11-27
BR0201904A (pt) 2003-04-22
NZ518950A (en) 2003-10-31
CA2386339A1 (en) 2002-11-15
ES2323526T3 (es) 2009-07-20
US20070259098A1 (en) 2007-11-08
CA2386339C (en) 2010-12-07
AR034335A1 (es) 2004-02-18
US7785650B2 (en) 2010-08-31
CN1388189A (zh) 2003-01-01
DE60231850D1 (de) 2009-05-20
KR20020087370A (ko) 2002-11-22
MXPA02004823A (es) 2005-10-04
CO5400143A1 (es) 2004-05-31
AU4061802A (en) 2002-11-21
EP1260219A3 (en) 2003-05-21
EP1260219B1 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
US7785650B2 (en) Method for dip coating dosage forms
US20030072731A1 (en) Dip coating compositions containing starch or dextrin
US20090092739A1 (en) Method of dip-coating dosage forms
EP1421932B1 (en) Polyacrylic film forming compositions
EP1297827B1 (en) Film forming composition comprising sucralose and hydrocolloid
US20030072729A1 (en) Simethicone as weight gain enhancer
WO2008008801A2 (en) Solid oral dosage vitamin and mineral compositions
EP1169022A1 (en) Elegant film coating system
EP1795187A1 (en) Film forming composition comprising sucralose and carrageenan
ES2367893T3 (es) Composiciones de recubrimiento por inmersión que contienen almidón o dextrina.
MXPA02004922A (es) Simeticona como incrementador de ganancia de ganancia en peso.

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GULIAN, CYNTHIA;GOWAN, WALTER G., JR.;PAREKH, KISHOR B.;AND OTHERS;REEL/FRAME:013025/0201;SIGNING DATES FROM 20020417 TO 20020422

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION